Tidal Therapeutics

Tidal Therapeutics was a preclinical-stage biotechnology company founded in 2019 and headquartered in Cambridge, Massachusetts. The company developed a novel mRNA-based platform for in vivo reprogramming of immune cells, using lipid nanoparticles specifically engineered to deliver mRNA to circulating T cells. This approach enabled transient expression of chimeric antigen receptors (CARs) directly on the surface of immune cells inside the body, creating a potential pathway to off-the-shelf CAR-T therapies without the need for ex vivo cell manipulation. In April 2021, Sanofi acquired Tidal Therapeutics for $160 million upfront with up to $470 million in total deal value, integrating the mRNA immunotherapy platform into Sanofi's RNA Center of Excellence.